NTLA

#4318
Intellia Therapeutics, Inc. - Common Stock
0.1 4 USD
-98.97%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
0.14
0.14
Intervallo Annuale
0.12
17.09
Variazione giornaliera
-98.97%
Variazione Mensile
-98.89%
Variazione di 6 mesi
-98.40%
Variazione Annuale
-98.97%
Chiusura Precedente
13.6 8
Open
0.1 4
Minimo
0.1 4
High
0.1 4
Volume
154
Apri il grafico completo Full chart

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
  • Market Capitalization 19.66 M
  • Employee 377
  • Founded 2014
  • CEO John Leonard
  • Website www.intelliatx.com
  • Headquarter Delaware, United States
  • FIGI BBG007KC7PB0
  • Industry Biotecnologia
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
-2.36
Rapporto prezzo/fatturato
14.4

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases. The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics. Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies.

Notizie